Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS®) platform for all human therapeutic applications, is pleased to announce that it has expanded its seed funding round to £13.5M. This investment Read More
Tags :Eli Lilly and Company
LONDON, United Kingdom, 6 July 2021 — MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA therapeutics, announces that Eli Lilly and Company has entered into a definitive agreement under which it will make Read More